Silvano has been a Venture Partner at Sofinnova since 2018. He is the founder and chairman of the board of BiovelocITA, the first Italian biotech accelerator, which was founded by Sofinnova. Silvano is also the founder of EOS S.p.A. (Ethical Oncology Science), a Sofinnova Capital V portfolio company, which was created in 2006, and where he served as its CEO until the company was acquired by Clovis Oncology, Inc. in 2013 for up to $470M.
Silvano co-founded and served as CEO of Novuspharma, a portfolio company of Sofinnova Capital III. In 2000, the company went public on the Italian market Nuovo Mercato, raising over €160M. Novuspharma was acquired by Cell Therapeutics, Inc. (CTI) in 2003.
Previously, Silvano was the Head of R&D at Boehringer Mannheim Italy. He holds a degree in organic chemistry from the University of Pisa. Sofinnova Partners was the lead investor in all these initiatives.